期刊文献+

扶正抗癌方通过PTEN/PI3K/Bad通路调控肺癌A549细胞增殖与凋亡 被引量:12

Effect of FZKA Decoction in Regulating A549 Proliferation and Apoptosis Via PTEN/PI3K/Bad
原文传递
导出
摘要 目的:观察扶正抗癌(FZKA)方对肺癌细胞A549增殖的调控作用,探讨其作用的分子机制。方法:以非小细胞肺癌细胞A549为研究对象,以FAKA方0.8,1.2,1.6,2.0,2.4,2.8,3.2 g·L^(-1)干预,空白组,分别孵育24,48,72 h后,设立采用噻唑蓝(MTT)比色法检测FZKA方对A549细胞活力的影响;以FAKA方1.2,1.6,2.0 g·L^(-1)干预,设立空白组,培养24 h后,采用实时荧光定量聚合酶链式反应(Real-time PCR)检测FZKA方对A549细胞人第10号染色体同源丢失性磷酸酶-张力蛋白(phosphatase and tensin homolog deleted on chromosome ten,PTEN)mRNA水平的影响;孵育24 h后,采用蛋白质免疫印迹法(Western blot)分析FZKA方对PTEN,磷脂酰肌醇3-激酶(phosphatidylinositol-3-kinase,PI3K),磷酸化的促凋亡蛋白Bad(Phospho-Bad,p-Bad)表达的影响并探讨其相关性。结果:与空白组比较,FZKA方能明显抑制A549细胞增殖,处理24 h后,FZKA从0.8 g·L^(-1)开始,处理48,72 h后,FZKA方从0.4 g·L^(-1)开始,细胞存活率明显降低(P<0.05,P<0.01);与空白组比较,处理24 h后,FZKA方从0.8 g·L^(-1)开始以浓度依赖性上调PTEN mRNA和蛋白的表达(P<0.05,P<0.01),FZKA方从1.6 g·L^(-1)开始以浓度依赖性下调PI3K蛋白表达(P<0.05,P<0.01),从2 h开始以时间依赖性上调p-Bad蛋白的表达(P<0.05,P<0.01)。结论:FZKA方可通过上调PTEN来调控下游PI3K/Akt/Bad通路相关蛋白的表达进而抑制A549的增殖,促进肺癌细胞凋亡。 Objective: To observe the effect of Fuzheng Kangai (FZKA) decoction on the proliferation and apoptosis, in order to discuss the molecular mechanism of apoptosis induced by FZKA decoction in A549 cells. Method: Non-small lung cancer cells (A549 cells) were taken as the research objects and treated for 24, 48, 72 h with 0 ( blank group) , 0.8, 1.2, 1.6, 2.0, 2.4, 2.8, 3.2 g·L-1FAKA decoction. Then, methyl-thiazolyl-tetrazolium (MTT) assay was used to detect the effect of FZKA decoction on the cell proliferation and apoptosis. A549 cells were treated for 24 h with 0 (blank group), 1.2, 1.6, 2.0 g·L-1. Then, quantitative Real-time PCR was used to detect the effect of FZKA decoction on PTEN mRNA expression. A549 ceils were treated for 24 h with 0 (blank group) , 0. 8, 1.2, 1.6, 2.0 g·L-1. Then, Western blot assay was used to detect the expressions of phosphatase and tensin homolog deleted on chromosome ten (PTEN), phosphatidylinositol-3-kinase (PI3K) and phospho-Bad (p-Bad), and discuss the relationship between them. Result: Compared with blank group, the proliferation of A549 cells were inhibited by FZKA decoction in concentration-dependent and time-dependent manners (P 〈 0.01 ). Compared with blank group, mRNA and protein expressions of PTEN were up-regulated in a concentration-dependent manner (P 〈 0.05, P 〈 0.01 ). Compared with blank group, the protein expression of PI3K was down-regulated in a concentration-dependent manner (P 〈 0.05, P 〈 0.01 ) , and p-Bad was down- regulated in a time-dependent manner (P 〈 0.05, P 〈 0.01 ). Conclusion: Apoptosis is induced by FZKA decoction by up-regulating PTEN and regulating PI3K/Akt/Bad pass way in A549 cells.
出处 《中国实验方剂学杂志》 CAS CSCD 北大核心 2017年第21期98-103,共6页 Chinese Journal of Experimental Traditional Medical Formulae
基金 国家自然科学基金项目(81503507,81273965) 广东省自然科学基金项目(2015A030310245) 广东省建设中医药强省科研课题项目(20141104)
关键词 扶正抗癌方 细胞增殖 人第10号染色体同源丢失性磷酸酶-张力蛋白 磷脂酰肌醇3-激酶 促凋亡蛋白 FZKA decoction proliferation phosphatase and tensin homolog deleted on chromosome ten phosphatidylinositol-3-kinase pro-apoptotic protein
  • 相关文献

参考文献7

二级参考文献50

  • 1项永兵,高玉堂.非吸烟女性肺癌危险因素的多分类logistic模型分析[J].中国卫生统计,2005,22(2):66-70. 被引量:30
  • 2邹小农.中国肺癌流行病学[J].中华肿瘤防治杂志,2007,14(12):881-883. 被引量:151
  • 3王梅,魏文强.中国肺癌患者住院人次增长现况及其主要影响因素分析[J].中国肿瘤,2007,16(9):672-675. 被引量:25
  • 4杨昌卫.扶正抗癌方联合吉非替尼治疗晚期非小细胞肺癌的临床研究[D].广州:广州中医药大学,2011.
  • 5Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin,2011,61 (2) :69.
  • 6Kelly K, Chansky K, Gaspar LE, et al. Phase III trim of maintenance ge- fitinib or placebo after concurrent chemoradiotherapy and docetaxel con- solidation in inoperable stage III non- small -cell lung cancer: SWOG S0023 [ J ]. J Clin Oneo1,2008,26 ( 15 ) :2450.
  • 7Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non - small - cell lung cancer with mutated EGFR [ J ]. N Engl J Med ,2010,362 (25) :2380.
  • 8Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus doeetaxel in patients with non - small - cell lung cancer harbouring mu- tations of the epidermal growth factor receptor ( WJTOG3405 ) : an open label, randomised phase 3 trial[ J ]. Lancet Onco1,2010,11 ( 2 ) : 121.
  • 9Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin - paeli- taxel in pulmonary adenoearcinoma[ J]. N Engl J Med ,2009,361 (10) : 947.
  • 10Mantovani A, Romero P, Karolina Palucka A K, et al. Tumour im- munity: effector response to tumour and role of the microenviron- ment [ J]. Lancet,2008,371 (9614) :771.

共引文献478

同被引文献196

引证文献12

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部